Evidence map›Paper›PMID 35251496›Full record

ArticleOncotarget2022

Transplantation of autologous bone marrow pre-loaded

Nancy Y Villa, Masmudur M Rahman, Joseph Mamola, Meaghen E Sharik, Ana Lemos de Matos, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Julia D'Isabella, Elizabeth Goras and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. OncolyticTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nancy Y VillaBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Masmudur M RahmanBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Joseph MamolaBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Meaghen E SharikDepartment of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Ana Lemos de MatosBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Jacquelyn KilbourneBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Kenneth LoweBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Juliane Daggett-VondrasBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Julia D'IsabellaBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Elizabeth GorasBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Marta ChesiDepartment of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
P Leif BergsagelDepartment of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Grant McFaddenBiodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
Arizona State University · USEmory University · USMayo Clinic in Arizona · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Studies in Poxvirus Host Range Genes and TropismR01AI080607 · NIAID · UNIVERSITY OF FLORIDA · PI RAHMAN, MASMUDUR MOHAMMED · 2009 to 2025
$5.6M
Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple MyelomaR01CA234181 · NCI · MAYO CLINIC ARIZONA · PI CHESI, MARTA · 2019 to 2023
$1.9M
NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA234181NIAID NIH HHS R01 AI080607
6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematological malignancy of plasma cells that remains incurable despite significant progress with myeloablative regimens and autologous stem cell transplantation for eligible patients and, more recently with T cell redirected immunotherapy. Recently, we reported that

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaMyxoma virusOncolytic VirotherapyOncolytic VirusesAnimalsBone MarrowBortezomibCyclophosphamideHumansImmune Checkpoint InhibitorsMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorTransplantation, AutologousBortezomibCyclophosphamideImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorautologous transplantationcombination therapymultiple myelomamyxoma virusoncolytic virus

Identifiers

PMID35251496
PMCPMC8893797
OpenAlexW4214904472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.